ProQR Therapeutics (PRQR) Income towards Parent Company (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Income towards Parent Company for 15 consecutive years, with -$15.2 million the latest figure, recorded in Q1 2026.

• Quarterly Income towards Parent Company fell 32.78% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.3 million (down 48.12% YoY) and the FY2025 annual result came in at -$48.0 million, down 51.94% from the prior year.
• Income towards Parent Company declined to -$15.2 million in Q1 2026 per PRQR's latest filing, from -$8.9 million in the prior quarter.
• Over the last five years, Income towards Parent Company for PRQR reached as high as -$3.1 million in Q2 2024 and fell as low as -$26.5 million in Q3 2022.
• A 5-year average of -$11.8 million and a median of -$10.5 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company soared 74.08% — and 2025, when it tumbled 377.75%.
• Year by year, Income towards Parent Company stood at -$15.1 million in 2022, then soared by 62.88% to -$5.6 million in 2023, then slumped by 86.47% to -$10.5 million in 2024, then grew by 14.78% to -$8.9 million in 2025, then slumped by 70.61% to -$15.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$15.2 million, -$8.9 million, and -$12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.